Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aciphex (rabeprazole) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Gastric pH on the Pharmacokinetics of Atazanavir

NCT01759875
View directory record Official record
Conditions
Healthy
Interventions
Ritonavir-boosted Atazanavir, Ritonavir-boosted Atazanavir plus Rabeprazole, Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 16 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

NCT00658632
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium, Esomeprazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
85
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Rabeprazole in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00222170
View directory record Official record
Conditions
Esophageal Reflux
Interventions
Rabeprazole
Drug
Lead sponsor
University of Kansas
Other
Eligibility
19 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 7, 2009 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers

NCT01237353
View directory record Official record
Conditions
Pharmacodynamic
Interventions
betaine hydrochloride, Rabeprazole
Dietary Supplement · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 59 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 3 Interventional Results available

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

NCT00838526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole ER, Ranitidine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Moline, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Rabeprazole
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 12, 2026, 3:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928
View directory record Official record
Conditions
Healthy Adults, Healthy
Interventions
PF-08049820, Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 3 Interventional

Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.

NCT00214552
View directory record Official record
Conditions
Asthma, Gastroesophageal Reflux Disease
Interventions
rabeprazole
Drug
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Richland, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

NCT02311946
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib Alone, Palbociclib + Rabeprazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Miami, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

NCT05602597
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg, Rabeprazole 40 mg
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 4 Interventional

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

NCT00304421
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole, pantoprazole
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants

NCT06054464
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PC14586, Rabeprazole, Famotidine
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability and Impact of Rabeprazole for PF-07799933, Food-Effect for PF-07799933 and PF-07799544

NCT07563894
View directory record Official record
Conditions
Healthy
Interventions
PF-07799933 tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fasted, PF-07799933 film-coated tablets with PF-07799544 fed, PF-07799933 film-coated tablets fasted, PF-07799933 film-coated tablets following rabeprazole pretreatment fasted
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

NCT00855361
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Rabeprazole sodium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Up to 44 Weeks
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Orange, California • Washington D.C., District of Columbia • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2013 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib

NCT01772290
View directory record Official record
Conditions
Healthy Volunteer
Interventions
fluconazole, itraconazole, rabeprazole, vismodegib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 12, 2026, 3:58 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of RO7890597 in Healthy Adult Volunteers

NCT07797478
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RO7890597, Placebo, Rabeprazole, Itraconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 12, 2026, 3:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib Food Effect and Proton Pump Inhibitor Study

NCT04645940
View directory record Official record
Conditions
Drug Interaction, Food-drug Interaction
Interventions
fruquintinib with food/fruquintinib without food/fruquintinib with rabeprazole, fruquintinib without food/fruquintinib with food/fruquintinib with rabeprazole
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 12, 2026, 3:58 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

NCT06916143
View directory record Official record
Conditions
Healthy Participants
Interventions
LY4100511, Rabeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 12, 2026, 3:58 PM EDT